TW282399B - - Google Patents
Info
- Publication number
- TW282399B TW282399B TW080103865A TW80103865A TW282399B TW 282399 B TW282399 B TW 282399B TW 080103865 A TW080103865 A TW 080103865A TW 80103865 A TW80103865 A TW 80103865A TW 282399 B TW282399 B TW 282399B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- optionally substituted
- hydrogen
- integer
- complex
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13634390 | 1990-05-25 | ||
| JP1533391 | 1991-02-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW282399B true TW282399B (enExample) | 1996-08-01 |
Family
ID=26351444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW080103865A TW282399B (enExample) | 1990-05-25 | 1991-05-20 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5196406A (enExample) |
| EP (1) | EP0461427B1 (enExample) |
| KR (1) | KR910019991A (enExample) |
| AT (1) | ATE148993T1 (enExample) |
| CA (1) | CA2043253C (enExample) |
| DE (1) | DE69124715T2 (enExample) |
| TW (1) | TW282399B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE196426T1 (de) * | 1991-06-21 | 2000-10-15 | Takeda Chemical Industries Ltd | Zyklodextrin-zusammensetzung enthaltend fumagillol-derivate |
| JP3122203B2 (ja) * | 1991-11-13 | 2001-01-09 | 塩水港精糖株式会社 | 新規ヘテロ分岐シクロデキストリンおよびその製造方法 |
| DE69330690T2 (de) * | 1992-01-30 | 2002-06-20 | Takeda Chemical Industries, Ltd. | Verfahren zur Herstellung hoch-wasserlöslicher Zyklodextrinkomplexe |
| DE69311278T2 (de) * | 1992-12-16 | 1997-10-30 | Takeda Chemical Industries Ltd | Stabile pharmazeutische Zubereitung mit Fumagillolderivaten |
| DE69417169T2 (de) * | 1993-09-24 | 1999-07-22 | Takeda Chemical Industries, Ltd., Osaka | Antineoplastische pharmazeutische Zusammensetzung enthaltend ein Fumagillolderivat und einen Platinkomplex |
| US5710148A (en) * | 1995-03-06 | 1998-01-20 | Senju Pharmaceuticals Co., Ltd. | Corneal opacification inhibitory composition |
| CA2210600A1 (en) * | 1996-07-17 | 1998-01-17 | Takashi Houkan | Inhibitor of tumor metastasis or recurrence |
| US6207704B1 (en) | 1997-06-09 | 2001-03-27 | Massachusetts Institute Of Technology | Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof |
| US8394813B2 (en) | 2000-11-14 | 2013-03-12 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
| US7169752B2 (en) * | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
| US20060014697A1 (en) * | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
| KR100455900B1 (ko) * | 2001-09-27 | 2004-11-12 | 주식회사 아이디알 | 새로운 푸마질롤 유도체 및 그의 제조방법 |
| ATE440094T1 (de) | 2001-09-27 | 2009-09-15 | Equispharm Co Ltd | Fumagillolderivate und verfahren zu deren herstellung |
| KR100451485B1 (ko) * | 2002-03-28 | 2004-10-06 | 주식회사종근당 | 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물 |
| US8133881B2 (en) | 2003-01-13 | 2012-03-13 | Shire Llc | Carbohydrate conjugates to prevent abuse of controlled substances |
| CA2731020A1 (en) * | 2008-07-18 | 2010-01-21 | Zafgen, Inc. | Use of antiangiogenic fumagillins in the treatment of obesity |
| US8642650B2 (en) | 2008-12-04 | 2014-02-04 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
| WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
| WO2011044506A2 (en) | 2009-10-09 | 2011-04-14 | Zafgen Corporation | Sulphone compounds and methods of making and using same |
| US8772333B2 (en) | 2010-01-08 | 2014-07-08 | Zafgen, Inc. | Fumigillol type compounds and methods of making and using same |
| WO2011085198A1 (en) | 2010-01-08 | 2011-07-14 | Zafgen Corporation | Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph) |
| WO2012012642A1 (en) | 2010-07-22 | 2012-01-26 | Zafgen Corporation | Tricyclic compounds and methds of making and using same |
| PH12013500934A1 (en) | 2010-11-09 | 2022-10-24 | Zafgen Inc | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
| CN103379905A (zh) | 2010-11-29 | 2013-10-30 | 扎夫根股份有限公司 | 使用非每天施用的6-0-(4-二甲基氨基乙氧基)肉桂酰烟曲霉醇治疗肥胖症 |
| CA2825408A1 (en) | 2011-01-26 | 2012-08-02 | Zafgen, Inc. | Tetrazole compounds and methods of making and using same |
| US9328082B2 (en) | 2011-03-08 | 2016-05-03 | Zafgen, Inc. | Oxaspiro[2.5]octane derivatives and analogs |
| FR2973376B1 (fr) * | 2011-03-28 | 2013-05-10 | Atlanthera | Derives utiles dans le traitement ou la prevention de tumeurs osseuses |
| AU2012253760B2 (en) | 2011-05-06 | 2016-02-04 | Zafgen, Inc. | Tricyclic pyrazole sulfonamide compounds and methods of making and using same |
| JP6062423B2 (ja) | 2011-05-06 | 2017-01-18 | ザフゲン，インコーポレイテッド | 部分飽和三環式化合物ならびにその製造および使用方法 |
| JP5941981B2 (ja) | 2011-05-06 | 2016-06-29 | ザフゲン，インコーポレイテッド | 三環式スルホンアミド化合物ならびにその製造および使用方法 |
| EP2763671A2 (en) | 2011-10-03 | 2014-08-13 | Zafgen, Inc. | Methods of treating age related disorders |
| EP2804866B1 (en) | 2012-01-18 | 2016-11-16 | Zafgen, Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
| KR20140112566A (ko) | 2012-01-18 | 2014-09-23 | 자프겐 인크. | 삼환식 설폰 화합물 그리고 그의 제조방법 및 그를 이용하는 방법 |
| BR112014027808A2 (pt) | 2012-05-07 | 2017-06-27 | Zafgen Inc | sal polimórfico do sal de oxalato de 6-o-(4-dimetilaminoetoxi) cinaroil fumagilol e métodos de produção e utilização do mesmo |
| MX2014013599A (es) | 2012-05-08 | 2015-05-11 | Zafgen Inc | Tratamiento de la obesidad hipotalamica con inhibidores de metap2. |
| WO2013169860A1 (en) | 2012-05-09 | 2013-11-14 | Zafgen, Inc. | Fumigillol type compounds and methods of making and using same |
| JP2015536983A (ja) | 2012-11-05 | 2015-12-24 | ザフゲン，インコーポレイテッド | 肥満の治療及び抑制における三環式化合物の使用 |
| EA028367B1 (ru) | 2012-11-05 | 2017-11-30 | Зафджен, Инк. | Способы лечения заболеваний печени |
| JP2015536981A (ja) | 2012-11-05 | 2015-12-24 | ザフゲン，インコーポレイテッド | 三環式化合物ならびにその製造および使用方法 |
| BR112015023390A2 (pt) | 2013-03-14 | 2017-07-18 | Zafgen Inc | métodos para tratar de doença renal e outros distúrbios |
| CN106432255A (zh) | 2015-08-11 | 2017-02-22 | 扎夫根公司 | 烟曲霉素醇螺环化合物和制备和使用其的方法 |
| AR105671A1 (es) | 2015-08-11 | 2017-10-25 | Zafgen Inc | Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3260714A (en) * | 1964-05-14 | 1966-07-12 | Upjohn Co | Quaternary ammonium salts of lincomycin |
| US3418414A (en) * | 1966-08-31 | 1968-12-24 | Upjohn Co | Trimethylsilyl ethers of lincomycin and its compounds |
| US3448097A (en) * | 1967-04-25 | 1969-06-03 | Upjohn Co | Lincomycin complexes and process for preparing the same |
| US3856943A (en) * | 1971-06-23 | 1974-12-24 | Upjohn Co | Compositions and process |
| US4278789A (en) * | 1979-11-23 | 1981-07-14 | The Upjohn Company | Lincomycin compounds |
| US4310660A (en) * | 1980-05-19 | 1982-01-12 | The Upjohn Company | Lincomycin compounds |
| US4383109A (en) * | 1981-04-20 | 1983-05-10 | The Upjohn Company | Lincomycin nucleotides |
| EP0094157B1 (en) * | 1982-04-30 | 1987-07-29 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its use |
| US4457916A (en) * | 1982-08-31 | 1984-07-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same |
| US4568741A (en) * | 1984-05-15 | 1986-02-04 | The Upjohn Company | Synthesis of 7-halo-7-deoxylincomycins |
| JPH0819004B2 (ja) * | 1986-12-26 | 1996-02-28 | 日清製粉株式会社 | 徐放性医薬製剤 |
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| SI8810082A8 (en) * | 1988-01-18 | 1995-12-31 | Lek Tovarna Farmacevtskih | Process for preparing new inclusion complex of nicardipine or its hydrochloride with beta-cyclodextrine |
| US5019562A (en) * | 1988-01-19 | 1991-05-28 | The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation | Growth inhibiting agent and the use thereof |
| JP2995069B2 (ja) * | 1988-01-19 | 1999-12-27 | フォークマン，モーゼス，ジューダ | 生長阻害剤およびその使用 |
| EP0325199B1 (en) * | 1988-01-19 | 1993-10-27 | Takeda Chemical Industries, Ltd. | Fumagillin as angiostatic agent |
| CA1321192C (en) * | 1988-04-20 | 1993-08-10 | Abdul Majid | Inclusion complexes of cyclodextrins by agglomeration |
| PH26256A (en) * | 1988-08-12 | 1992-04-01 | Fujisawa Pharmaceutical Co | Oxaspiro [2,5] octane derivative |
| US4954496A (en) * | 1988-08-12 | 1990-09-04 | Fujisawa Pharmaceutical Company, Ltd. | Cyclohexane derivatives and pharmaceutical compositions |
| DE68915900T2 (de) * | 1988-09-01 | 1994-11-24 | Childrens Medical Center | Angiogenese hemmendes Mittel. |
| ES2099064T3 (es) * | 1988-09-01 | 1997-05-16 | Takeda Chemical Industries Ltd | Derivados de fumagillol. |
| EP0415294A3 (en) * | 1989-08-31 | 1991-06-12 | Takeda Chemical Industries, Ltd. | Cyclohexanol derivatives, production and use thereof |
-
1991
- 1991-05-20 TW TW080103865A patent/TW282399B/zh active
- 1991-05-22 EP EP91108225A patent/EP0461427B1/en not_active Expired - Lifetime
- 1991-05-22 DE DE69124715T patent/DE69124715T2/de not_active Expired - Fee Related
- 1991-05-22 AT AT91108225T patent/ATE148993T1/de active
- 1991-05-23 US US07/704,347 patent/US5196406A/en not_active Expired - Fee Related
- 1991-05-24 CA CA002043253A patent/CA2043253C/en not_active Expired - Fee Related
- 1991-05-25 KR KR1019910008574A patent/KR910019991A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP0461427B1 (en) | 1997-02-19 |
| ATE148993T1 (de) | 1997-03-15 |
| US5196406A (en) | 1993-03-23 |
| CA2043253A1 (en) | 1991-11-26 |
| CA2043253C (en) | 2002-10-15 |
| DE69124715D1 (de) | 1997-03-27 |
| DE69124715T2 (de) | 1997-06-05 |
| KR910019991A (ko) | 1991-12-19 |
| EP0461427A2 (en) | 1991-12-18 |
| EP0461427A3 (en) | 1992-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW282399B (enExample) | ||
| ATE82966T1 (de) | Pyridincarboxamid-derivate und ihre verwendung als fungizides mittel. | |
| ATE205092T1 (de) | Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe | |
| HU9601505D0 (en) | Novel imidazole derivative and process for producing the same | |
| NO307255B1 (no) | Nye forbindelser og antitumormidler | |
| ES2094204T3 (es) | Derivados de piperazina. | |
| FI882590A0 (fi) | Analogiamenetelmä lääkeaineena käytettävän pyridiinijohdannaisen valmistamiseksi | |
| ATE232528T1 (de) | Pyrimidinylpyrazolderivate | |
| LV10235A (lv) | Jauni esteri to iegusanas panemiens farmaceitiska kompozicija arstesanas metode | |
| GR3001994T3 (en) | A thiophene derivative and process for preparing the same | |
| GR3018167T3 (en) | Naphthoic acid derivative. | |
| DK183789A (da) | 2-alkyl-3-benzoylbenzofuraner og laegemidler indeholdende disse | |
| GB9012223D0 (en) | Amines | |
| DE69319859D1 (de) | Neue tetracyclische verbindungen | |
| ATE148128T1 (de) | Anthracyclinglycosid-derivate und verfahren zu ihrer herstellung | |
| EP0730863A3 (en) | A corneal opacification inhibitory composition comprising a fumagillol derivative | |
| AU5173293A (en) | Novel quaternary ammonium salts and use thereof as medicine | |
| EP0741132A4 (en) | INDOL DERIVATIVES | |
| DE69828087D1 (de) | Aminderivate | |
| KR927003608A (ko) | 유기주석 화합물의 합성방법과 그의 용도 | |
| ATE165094T1 (de) | Zytotoxische verbindungen | |
| DE3361149D1 (en) | Triazole derivatives, process for their preparation and fungicides containing them | |
| ATE100449T1 (de) | 1,3-dioxolan-benzoesaeure und derivate davon. |